Start with stage, ER/PR and HER2 reports, exact prior treatments and timing. An early-stage study before surgery, a study for residual disease after surgery, and a metastatic trial may use the same drug but have different entry requirements.
Answer a few questions to find clinical trials matched to your specific Breast Cancer situation.
A thorough search takes ~15 minutes — we'll email your results. No sign-up.
Before surgery: neoadjuvant studies may require untreated disease, a particular size/nodal stage or response-assessment sequence.
After surgery: adjuvant protocols may depend on pathological complete response (pCR), residual invasive disease, recurrence risk and time since treatment. A chemotherapy-omission trial does not mean omission is already appropriate for everyone.
Locoregional recurrence: some studies address treatment after a local recurrence has been treated, rather than distant metastatic disease.
Advanced/metastatic: first-line, maintenance, endocrine-resistant and post-ADC cohorts have different exposure/progression requirements. Bring the names of every endocrine drug, CDK4/6 inhibitor, HER2 therapy, ADC and chemotherapy received.
Current Clinical Trial Landscape
Registry snapshot, November 15, 2026: the worldwide ClinicalTrials.gov search for Breast Cancer, interventional studies and Recruiting status returned 1,860 records. This broad result is not the number suitable for one person. Open the filtered registry search.
Research spans endocrine/pathway combinations, HER2-directed drugs, ADCs, immunotherapy, treatment sequencing, early-stage optimization and supportive care. These categories overlap; no fresh class-specific totals are claimed.
How Breast Subtypes and Biomarkers Fit Together
HR/ER/PR: bring receptor percentages and pathology reports. HR-positive and selected ER-low cohorts can have different rules. HR-negative disease should not be silently grouped with HR-positive protocols.
HER2-positive: IHC and ISH results select HER2-directed studies. A HER2 mutation is not the same as HER2 protein overexpression or gene amplification.
HER2-low: commonly IHC 1+ or IHC 2+/ISH-negative. HER2-ultralow: IHC 0 with membrane staining in the relevant assay/indication. IHC 0: some trials include both absent and faint membrane staining; do not assume every IHC 0 protocol means no staining.
TNBC: ER/PR-negative and HER2-negative disease. NCI describes this subtype. HER2-low expression and TNBC labels can overlap; use the actual IHC/ISH and hormone-receptor values.
BRCA1/2, PALB2, ESR1, PIK3CA/AKT/PTEN and PD-L1: exact variants, germline versus tumor testing, assay/score and sample date may matter. A finding suggests a question to check, not automatic eligibility for every drug in a class.
These selected examples are not a complete treatment guide. Discuss current local labels and alternatives with your oncology team; do not change treatment on this page alone.
Drug Names and Prior ADC Exposure
Sacituzumab tirumotecan, SKB264 and MK-2870 name the same study drug; sacituzumab govitecan is a different drug. T-DXd, SHR-A1811 and other HER2 ADCs are not interchangeable products. A drug's target does not establish that every subtype can enter its trial: patritumab deruxtecan NCT07060807 selects HR-positive/HER2-negative disease after specified endocrine/CDK4/6 treatment.
Have your stage, pathology and treatment history ready?
All 57 cited records were checked November 15, 2026: 51 recruiting, five active but not recruiting and one unknown. Non-enrolling and unknown records are separated at the end. Every example carries its phase and recruitment label; a recruiting record does not guarantee an open local site/cohort or personal eligibility.
HR-positive/HER2-negative advanced disease: endocrine and pathway approaches
NCT07085767 — Palazestrant plus ribociclib first-line for ER-positive/HER2-negative advanced disease (Phase 3; recruiting).
NCT07647328 — Camizestrant plus ribociclib for previously untreated ER-positive/HER2-negative advanced disease; this research setting differs from the ESR1-triggered approved switch strategy (Phase 3; recruiting).
NCT06790693 — Inavolisib plus CDK4/6 inhibitor/letrozole versus placebo plus that backbone for endocrine-sensitive PIK3CA-mutated advanced disease (Phase 3; recruiting).
NCT06982521 — RLY-2608/fulvestrant versus capivasertib/fulvestrant in PIK3CA-mutated HR-positive/HER2-negative advanced disease (Phase 3; recruiting).
NCT07174336 — Tersolisib plus endocrine/CDK4/6 treatments for PIK3CA-selected HR-positive/HER2-negative advanced disease; study parts have different prior-treatment limits (Phase 3; recruiting).
NCT06312176 — MK-2870-010: sacituzumab tirumotecan alone or with pembrolizumab versus physician-selected treatment in HR-positive/HER2-negative unresectable/metastatic disease (Phase 3; recruiting).
NCT06383767 — ESG401 for HR-positive/HER2-negative advanced disease (Phase 3; recruiting).
NCT07071337 — SKB264 versus chemotherapy after endocrine-therapy failure in HR-positive/HER2-negative disease; protocol-specific HER2 criteria apply (Phase 3; recruiting).
NCT07648914 — PANKU-Breast03: BL-B01D1 versus chemotherapy after endocrine-therapy failure in HR-positive/HER2-negative unresectable/recurrent/metastatic disease; this is not a TNBC protocol (Phase 3; recruiting).
NCT07060807 — MK-1022-016: patritumab deruxtecan versus physician-selected treatment for HR-positive/HER2-negative advanced disease after CDK4/6/endocrine progression or recurrence; HER3 testing and other prior-treatment restrictions apply, not a pan-subtype trial (Phase 3; recruiting).
HR-positive/HER2-negative early-stage and locoregional recurrence studies
NCT05774951 — CAMBRIA-1: camizestrant after at least two years of standard adjuvant endocrine therapy for ER-positive/HER2-negative early disease (Phase 3; recruiting).
NCT06341621 — Chemotherapy omission with extended adjuvant abemaciclib for selected ER-positive/HER2-negative disease with one to three positive nodes; omission is tested by protocol, not a general recommendation (Phase 3; recruiting).
NCT07190443 — AURA/JCOG2313: adjuvant abemaciclib after locoregional recurrence of HR-positive/HER2-negative disease (Phase 3; recruiting).
NCT07671885 — Young HOPE/JCOG2402: response-guided neoadjuvant endocrine treatment to inform adjuvant therapy in premenopausal HR-positive/HER2-negative disease (Phase 3; recruiting).
NCT07106632 — Genomic-test-guided adjuvant chemotherapy decisions in young patients with hormone-dependent disease (Phase 3; recruiting).
NCT07391774 — RxFINE-Low: endocrine therapy/ribociclib versus chemotherapy followed by endocrine therapy/ribociclib in high anatomic-stage, low recurrence-risk disease; an early/adjuvant setting, not first-line metastatic treatment (Phase 3; recruiting).
HER2-positive first-line advanced disease and maintenance
NCT07518173 — BL-M07D1 plus pertuzumab versus docetaxel/trastuzumab/pertuzumab first-line for HER2-positive recurrent/metastatic disease (Phase 3; recruiting).
NCT05894239 — Inavolisib plus Phesgo versus placebo plus Phesgo as maintenance after induction in previously untreated PIK3CA-mutated HER2-positive advanced disease; not a general later-line combination (Phase 3; recruiting).
HER2-positive previously treated advanced disease
NCT06435429 — Zanidatamab plus chemotherapy versus trastuzumab plus chemotherapy after progression on or intolerance to T-DXd, with two to four metastatic HER2-directed lines; the listed arms do not add pertuzumab, and this is not first-line (Phase 3; recruiting).
NCT06846437 — JSKN003 versus T-DM1 for HER2-positive advanced disease; prior-treatment requirements apply (Phase 3; recruiting).
NCT07008976 — TQB2102 versus T-DM1 for HER2-positive advanced disease (Phase 3; recruiting).
NCT07673029 — GQ1005 versus T-DM1 for HER2-positive unresectable/metastatic disease; comparator T-DM1 does not mean patients must already have progressed on T-DM1 (Phase 3; recruiting).
NCT07294508 — HLX22 plus HLX87 for HER2-positive recurrent/metastatic disease; protocol-specific cohort/prior-treatment criteria apply (Phase 2/3; recruiting).
HER2-positive neoadjuvant and postoperative studies
NCT06891833 — BL-M07D1 with or without pertuzumab versus docetaxel/carboplatin/trastuzumab/pertuzumab before surgery (Phase 2/3; recruiting).
NCT05883852 — EC-THP versus TCbHP before surgery in HER2-positive node-positive early disease (Phase 3; recruiting).
NCT07393425 — SHR-A1811 plus pertuzumab before surgery for HER2-positive disease; use the protocol's drug code rather than treating all HER2 ADCs as T-DXd (Phase 2; recruiting).
NCT06876714 — ShortStop-HER2: 12 versus six months of HER2-targeted therapy after pathological complete response to chemotherapy/trastuzumab (Phase 3; recruiting).
NCT06992882 — ORCHID-PLUS: oral chemotherapy/trastuzumab versus paclitaxel/trastuzumab after surgery for HER2-positive node-negative early disease (Phase 3; recruiting).
TNBC first-line locally advanced or metastatic studies
NCT06926868 — IZABRIGHT-Breast01: izalontamab brengitecan versus chemotherapy in previously untreated advanced TNBC ineligible for anti-PD-(L)1 therapy (Phase 2/3; recruiting).
NCT06767527 — AK112/ivonescimab or placebo plus nab-paclitaxel first-line for inoperable locally advanced/metastatic TNBC (Phase 3; recruiting).
NCT07173751 — ROSETTA Breast-01: pumitamig for TNBC; study-specific PD-L1, prior-treatment and comparator rules apply (Phase 3; recruiting).
NCT07111832 — SHR-A1811 plus adebrelimab versus toripalimab/nab-paclitaxel first-line for PD-L1-positive metastatic TNBC (Phase 3; recruiting).
NCT06103864 — TROPION-Breast05: datopotamab deruxtecan with or without durvalumab versus chemotherapy/pembrolizumab first-line for PD-L1-positive unresectable recurrent/metastatic TNBC (Phase 3; recruiting).
NCT06841354 — TroFuse-011: sacituzumab tirumotecan alone or with pembrolizumab versus chemotherapy in previously untreated advanced TNBC, excluding PD-L1 CPS at least 10; this is not a later-line study (Phase 3; recruiting).
TNBC previously treated advanced disease
NCT07544056 — BEBT-209 plus carboplatin/gemcitabine versus that chemotherapy after one to two prior systemic advanced-disease therapies, with protocol-defined early-relapse counting (Phase 2/3; recruiting).
TNBC or selected HR-low early-stage and residual-disease studies
NCT06081244 — ADAPT-TN-III: sacituzumab govitecan versus sacituzumab govitecan/pembrolizumab before surgery in selected lower-risk early TNBC (Phase 3; recruiting).
NCT06606730 — Personalizing pembrolizumab use after a strong response in early TNBC; response and prior-treatment sequence matter (Phase 3; recruiting).
NCT05999149 — Camrelizumab/chemotherapy with or without famitinib before surgery for TNBC (Phase 3; recruiting).
NCT03150576 — Platinum/PARP-inhibitor neoadjuvant research for TNBC and/or germline BRCA-positive breast cancer; cohort requirements differ (Phase 2/3; recruiting).
NCT06393374 — MK-2870-012: sacituzumab tirumotecan plus pembrolizumab versus physician-selected treatment for TNBC with residual disease after neoadjuvant therapy (Phase 3; recruiting).
NCT06533384 — PARP inhibitor or capecitabine plus PD-1 inhibitor as adjuvant therapy for high-risk TNBC (Phase 3; recruiting).
NCT06966700 — MK-2870-032: neoadjuvant sacituzumab tirumotecan/pembrolizumab strategy for untreated early TNBC or selected ER-low/HER2-negative disease; not a generic metastatic breast protocol (Phase 3; recruiting).
HER2-low, ultralow and IHC 0 research
NCT06486883 — T-DXd versus CDK4/6-based endocrine treatment first-line for HR-positive HER2-low/ultralow advanced disease classified as non-luminal; this is a selected molecular subtype (Phase 2; recruiting).
NCT05950945 — T-DXd in HR-positive or HR-negative HER2-low or IHC 0 advanced disease after one to two metastatic treatment lines, without prior ADC or metastatic HER2 therapy; specific endocrine restrictions also apply (Phase 3; recruiting).
NCT07205822 — Datopotamab deruxtecan before metastatic chemotherapy in HR-positive HER2 IHC 0 disease; the protocol includes both no staining and specified faint membrane staining, not only HER2-null (Phase 3; recruiting).
NCT07669467 — Nuvastatic for cancer-related fatigue in TNBC; symptom management is distinct from a study testing tumor response or survival (Phase 3; recruiting).
Active, not recruiting
NCT04784715 — DESTINY-Breast09: T-DXd with or without pertuzumab versus taxane/trastuzumab/pertuzumab in first-line HER2-positive metastatic disease (Phase 3; active not recruiting).
NCT05952557 — CAMBRIA-2: adjuvant camizestrant for ER-positive/HER2-negative early disease (Phase 3; active not recruiting).
NCT05827081 — Ribociclib plus endocrine therapy in early disease; registry phase is 3 and study described as Phase IIIb (Phase 3; active not recruiting).
NCT06065748 — pionERA: giredestrant versus fulvestrant, each with a CDK4/6 inhibitor, in advanced disease resistant to adjuvant endocrine therapy; not an unrestricted post-metastatic-CDK4/6 setting (Phase 3; active not recruiting).
NCT06279364 — SKB264 versus chemotherapy in unresectable recurrent/metastatic TNBC (Phase 3; active not recruiting).
Recruitment unknown: confirm current availability
NCT04547907 — Nab-PHP versus TCbHP before surgery for HER2-positive early disease; current registry status is unknown (Phase 3; unknown).
Frequently Asked Questions
How do I find breast cancer trials for my subtype?
Bring stage, surgery and recurrence status, ER/PR percentages, HER2 IHC/ISH reports, exact biomarkers and prior treatment with dates and progression history. ClinTrialFinder suggests studies for discussion; the study team confirms protocol eligibility and site availability.
How many breast cancer trials are recruiting?
The November 15, 2026 worldwide ClinicalTrials.gov query for Breast Cancer, interventional studies and Recruiting status returned 1,860 records. This is a broad search, not a personalized count. Of the 57 selected records here, 51 were recruiting; five were active but not recruiting and one had unknown status.
Are HER2-positive, HER2-low, HER2-ultralow and IHC 0 interchangeable?
No. HER2-positive, low and ultralow labels depend on IHC/ISH findings and the relevant protocol or drug indication. Some IHC 0 trials include both absent and faint membrane staining. HR status and prior treatment still matter; bring the original report instead of relying on a shorthand subtype.
Can someone who already had surgery enter a neoadjuvant or adjuvant study?
It depends on the protocol. Neoadjuvant studies generally start before surgery, while adjuvant studies may require specific pathological risk, residual disease or a minimum/maximum duration of prior endocrine therapy. A high stage alone does not establish eligibility for a metastatic trial.
Does a breast ADC trial accept every subtype or someone who already had an ADC?
No. NCT07060807 selects HR-positive/HER2-negative advanced disease after specified endocrine/CDK4/6 treatment, and NCT05950945 excludes prior ADC exposure. Zanidatamab NCT06435429 instead requires prior T-DXd progression or intolerance and multiple HER2-directed lines. Read the actual treatment and subtype criteria.
Is camizestrant research the same as the ESR1-triggered approved switch?
No. The approved camizestrant/CDK4/6 switch follows detection of an ESR1 mutation during aromatase-inhibitor/CDK4/6 therapy and was studied without progression. Early-stage CAMBRIA and upfront advanced-disease studies are different cohorts. An ESR1 result alone does not establish eligibility for every camizestrant study.
Find Breast Cancer Trials Matched to Your Situation
Enter your subtype, biomarkers (HER2, ER/PR, BRCA, PIK3CA), and treatment history to get AI-matched results in minutes.
This page is for information only and is not medical advice. ClinTrialFinder helps you find clinical trials that may match your situation, but enrollment decisions and treatment choices should always be made with your oncologist or healthcare team. Trial eligibility, recruitment status, and treatment details can change — verify directly with the trial sponsor or on ClinicalTrials.gov before acting on any information here.